Q-omics provides the consensus-scored RWDD2A profile across patient tissues and cancer cell-line models. RWDD2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RWDD2A is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, RWDD2A RNA expression shows 20,379 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KICH, and UVM as cancer lineages where RWDD2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RWDD2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RWDD2A survival associations across molecular data types. RWDD2A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RWDD2A RNA expression–survival associations across cancer types. High RWDD2A expression shows unfavorable associations in KICH, but favorable associations in SKCM, PAAD, HNSC, LGG and OV. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RWDD2A RNA expression.
This table summarizes RWDD2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RWDD2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RWDD2A shows lower tumor expression in KICH, THCA and LUSC and higher tumor expression in COAD, KIRC and LIHC. The KICH box plot shows higher RWDD2A RNA expression in normal versus tumor tissue (log2 FC = −1.581, t-test p < 0.001).
This table shows molecular features associated with RWDD2A in patient tissues and cancer cell lines. In patient samples, RWDD2A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RWDD2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
